ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.707,28
-0,87%
S&P 500
5.266,95
-0,74%
US Dollar vs BRL
5,2031
-0,01%
Bitcoin
67.914,93
0,49%
Brent Oil
83,315
-0,07%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) Notícias

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLUE
DataHoraFonteTítuloCódigoCompanhia
30/05/202408:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Leadership Team PromotionsNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/05/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel DiseaseNASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202417:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/05/202417:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202408:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
02/05/202417:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
14/03/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/03/202408:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
31/01/202409:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/01/202409:15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
04/01/202418:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
03/01/202409:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/11/202309:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/11/202309:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202312:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/10/202317:30GlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202308:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202308:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
18/08/202317:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/08/202318:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
10/08/202308:15GlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/07/202308:30GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/06/202317:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GLUEMonte Rosa Therapeutics Inc
14/06/202317:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202317:30GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Upcoming Investor and Industry ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
23/05/202308:30GlobeNewswire Inc.Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:GLUE

Seu Histórico Recente

BIT
P1PV81
BNP Paribas Issuance
GATE
COMBOETH
Furucombo
BIT
P186W6
BNP Paribas Issuance
TSX
SPLT
Brompton Split Corp Pref...
BIT
P1DV44
BNP Paribas Issuance
BIT
P1OJB1
BNP Paribas Issuance
NYSE
NMS
Nuveen Minnesota Quality...
AMEX
BOUT
Innovator Ibd Breakout O...
BIT
UR9UGU
UniCredit Bank
BIT
REEVO
Reevo
BIT
P1OVP6
BNP Paribas Issuance
TG
ACBB
Alpha Services
NYSE
GGZ-A
Gabelli Global Small and...
BIT
P1IN80
BNP Paribas Issuance
EU
I3FNG
GRANITE 3FNG INAV
BMF
VF3F25P000800
VF3F25P000800 - 01/2025
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados